{
     "PMID": "24607349",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20141209",
     "LR": "20161125",
     "IS": "1873-7544 (Electronic) 0306-4522 (Linking)",
     "VI": "267",
     "DP": "2014 May 16",
     "TI": "Neuroprotective effect of dimebon against ischemic neuronal damage.",
     "PG": "11-21",
     "LID": "10.1016/j.neuroscience.2014.02.025 [doi] S0306-4522(14)00137-7 [pii]",
     "AB": "Dimebon (dimebolin or latrepirdine), originally developed as an anti-histaminic drug, has been investigated and proposed as a cognitive enhancer for treating neurodegenerative disorders such as Alzheimer's and Huntington's diseases, and more recently schizophrenia. This study was conducted to evaluate the potential neuroprotective effect of dimebon during brain ischemia using rat hippocampal slices subjected to oxygen and glucose deprivation followed by a reoxygenation period (OGD/Reox) or glutamate excitotoxicity. Dimebon, incubated during the OGD/Reox period, caused a concentration -dependent protective effect of hippocampal slices; maximum protection (85%) was achieved at 30muM. Mitochondrial membrane depolarization, reactive oxygen species of oxygen (ROS) production, nitric oxide synthase (iNOS) induction and translocation of p65 to the nucleus induced by OGD/Reox were significantly reduced in dimebon-treated hippocampal slices. In the glutamate-induced excitotoxicity model, dimebon also afforded a concentration-dependent protective effect that was significantly higher than that obtained with memantine, a non-competitive N-methyl-d-aspartate (NMDA) antagonist. When changes in the intracellular calcium concentration were evaluated in Fluo-4-loaded rat hippocampal neurons, glutamate-induced calcium transients were reduced by 20% with dimebon. These results suggest that dimebon could counteract different pathophysiological processes during ischemic brain damage and, could therefore, be considered as a novel therapeutic strategy for cerebral ischemia-reoxygenation injury.",
     "CI": [
          "Copyright (c) 2014 IBRO. Published by Elsevier Ltd. All rights reserved."
     ],
     "FAU": [
          "Egea, J",
          "Romero, A",
          "Parada, E",
          "Leon, R",
          "Dal-Cim, T",
          "Lopez, M G"
     ],
     "AU": [
          "Egea J",
          "Romero A",
          "Parada E",
          "Leon R",
          "Dal-Cim T",
          "Lopez MG"
     ],
     "AD": "Instituto Teofilo Hernando, Universidad Autonoma de Madrid, Madrid, Spain; Departamento de Farmacologia y Terapeutica, Facultad de Medicina, Universidad Autonoma de Madrid, Madrid, Spain. Instituto Teofilo Hernando, Universidad Autonoma de Madrid, Madrid, Spain; Departamento de Farmacologia y Terapeutica, Facultad de Medicina, Universidad Autonoma de Madrid, Madrid, Spain. Electronic address: manarome@ucm.es. Instituto Teofilo Hernando, Universidad Autonoma de Madrid, Madrid, Spain; Departamento de Farmacologia y Terapeutica, Facultad de Medicina, Universidad Autonoma de Madrid, Madrid, Spain. Instituto Teofilo Hernando, Universidad Autonoma de Madrid, Madrid, Spain; Departamento de Farmacologia y Terapeutica, Facultad de Medicina, Universidad Autonoma de Madrid, Madrid, Spain; Instituto de Investigacion Sanitaria Hospital Universitario la Princesa, Universidad Autonoma de Madrid, Madrid, Spain. Departamento de Bioquimica, Universidade Federal de Santa Catarina, Florianopolis, Brazil. Instituto Teofilo Hernando, Universidad Autonoma de Madrid, Madrid, Spain; Departamento de Farmacologia y Terapeutica, Facultad de Medicina, Universidad Autonoma de Madrid, Madrid, Spain.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20140304",
     "PL": "United States",
     "TA": "Neuroscience",
     "JT": "Neuroscience",
     "JID": "7605074",
     "RN": [
          "0 (Indoles)",
          "0 (Neuroprotective Agents)",
          "0 (Reactive Oxygen Species)",
          "IY9XDZ35W2 (Glucose)",
          "OD9237K1Z6 (latrepirdine)"
     ],
     "SB": "IM",
     "MH": [
          "Animals",
          "Cell Nucleus/drug effects/metabolism",
          "Cell Survival/drug effects",
          "Cells, Cultured",
          "Cytosol/drug effects/metabolism",
          "Embryo, Mammalian",
          "Glucose/deficiency",
          "Hippocampus/*pathology",
          "Hypoxia/pathology",
          "In Vitro Techniques",
          "Indoles/*pharmacology",
          "Ischemia/*pathology",
          "Male",
          "Membrane Potential, Mitochondrial/drug effects",
          "Neurons/cytology/*drug effects",
          "Neuroprotective Agents/*pharmacology",
          "Rats",
          "Rats, Sprague-Dawley",
          "Reactive Oxygen Species/metabolism",
          "Time Factors"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "dimebon",
          "hippocampal neurons",
          "hippocampal slices",
          "ischemia",
          "neuroprotection",
          "oxygen-glucose deprivation"
     ],
     "EDAT": "2014/03/13 06:00",
     "MHDA": "2014/12/15 06:00",
     "CRDT": [
          "2014/03/11 06:00"
     ],
     "PHST": [
          "2014/01/18 00:00 [received]",
          "2014/02/19 00:00 [accepted]",
          "2014/03/11 06:00 [entrez]",
          "2014/03/13 06:00 [pubmed]",
          "2014/12/15 06:00 [medline]"
     ],
     "AID": [
          "S0306-4522(14)00137-7 [pii]",
          "10.1016/j.neuroscience.2014.02.025 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Neuroscience. 2014 May 16;267:11-21. doi: 10.1016/j.neuroscience.2014.02.025. Epub 2014 Mar 4.",
     "term": "hippocampus"
}